Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering.

Cells·2026
Same author

I-TEP: A Simple and Affordable Method to Measure Permeability in Reconstructed Tissues Combined with DAMO-TSC-Based Urea Assay.

Methods and protocols·2026
Same author

Regenerative Medicine Approaches to Stress Urinary Incontinence.

Biomimetics (Basel, Switzerland)·2026
Same author

Erratum: Publisher Correction: Assessing the Relationship Between Bladder Cancer Cell Contractile Phenotypes and Their Invasive Properties.

Cellular and molecular bioengineering·2026
Same author

Assessing the Relationship Between Bladder Cancer cell Contractile Phenotypes and their Invasive Properties.

Cellular and molecular bioengineering·2026
Same author

A Youth-Led Evaluation of Adolescent Involvement in a Project on Development of Guidelines for Adolescent Involvement in Health Research.

Health expectations : an international journal of public participation in health care and health policy·2026
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Double anticholinergic therapy for refractory overactive bladder.

Stéphane Bolduc1, Katherine Moore, Sylvie Lebel

  • 1Division of Urology, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, Québec, Canada. sbolduc_2002@yahoo.ca

The Journal of Urology
|August 22, 2009
PubMed
Summary
This summary is machine-generated.

Dual anticholinergic therapy effectively treated refractory overactive bladder in children when single medications failed, improving continence and bladder capacity with good tolerability and safety.

Related Experiment Videos

Last Updated: Jun 20, 2026

Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Area of Science:

  • Pediatric Urology
  • Pharmacology
  • Urodynamics

Background:

  • Refractory overactive bladder (OAB) in children often presents challenges for effective management.
  • Single-agent anticholinergic therapy may fail to achieve adequate symptom control in some pediatric patients.
  • Optimizing medical therapy is crucial to avoid invasive interventions.

Purpose of the Study:

  • To evaluate the efficacy, tolerability, and safety of dual anticholinergic medication for children with refractory overactive bladder (OAB).
  • To assess the potential of combining oxybutynin, tolterodine, and/or solifenacin in pediatric OAB management.
  • To determine if this approach offers a viable alternative to surgery.

Main Methods:

  • Prospective, open-label study of children with refractory OAB and incontinence.
  • Inclusion criteria: persistent symptoms despite optimal single-agent anticholinergic therapy and behavioral interventions.
  • Primary endpoint: efficacy for continence; secondary endpoints: tolerability and safety.

Main Results:

  • Dual anticholinergic therapy significantly improved urodynamic capacity (192 to 380 ml) and decreased maximal contraction pressure (77 to 18 cm H2O).
  • All patients showed improved continence, with 17 achieving dryness.
  • Side effects were mostly mild, and blood tests and ECGs remained normal.

Conclusions:

  • Dual anticholinergic therapy is an effective and safe nonoperative option for children with refractory overactive bladder (OAB).
  • This innovative approach demonstrated patient and family satisfaction.
  • It presents a serious alternative to surgical interventions for pediatric OAB.